{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+dose+formulation&page=2",
    "query": {
      "intervention": "High dose formulation",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+dose+formulation&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T09:52:35.640Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02853435",
      "title": "To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infections, Bacterial"
      ],
      "interventions": [
        {
          "name": "Gepotidacin RC Tablet",
          "type": "DRUG"
        },
        {
          "name": "Gepotidacin HSWG Tablet",
          "type": "DRUG"
        },
        {
          "name": "Gepotidacin Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 48,
      "start_date": "2016-08-04",
      "completion_date": "2017-10-17",
      "has_results": true,
      "last_update_posted_date": "2020-10-08",
      "last_synced_at": "2026-09-12T09:52:35.640Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • Austin, Texas",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02853435"
    },
    {
      "nct_id": "NCT00941304",
      "title": "Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dental Pain"
      ],
      "interventions": [
        {
          "name": "Oxycodone",
          "type": "DRUG"
        },
        {
          "name": "Buprenorphine",
          "type": "DRUG"
        },
        {
          "name": "Placebo Film",
          "type": "DRUG"
        },
        {
          "name": "Placebo Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioDelivery Sciences International",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 153,
      "start_date": "2009-08",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2017-02-27",
      "last_synced_at": "2026-09-12T09:52:35.640Z",
      "location_count": 3,
      "location_summary": "Austin, Texas • San Marcos, Texas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "San Marcos",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00941304"
    },
    {
      "nct_id": "NCT01098513",
      "title": "GSK1349572 Relative Bioavailability Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK1349572 formulation AP",
          "type": "DRUG"
        },
        {
          "name": "GSK1349572 formulation AW",
          "type": "DRUG"
        },
        {
          "name": "GSK1349572 formulation AX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2010-04",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2017-06-09",
      "last_synced_at": "2026-09-12T09:52:35.640Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01098513"
    },
    {
      "nct_id": "NCT03130556",
      "title": "A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Glasdegib",
          "type": "DRUG"
        },
        {
          "name": "High Fat, High Calorie Meal",
          "type": "OTHER"
        },
        {
          "name": "Rabeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2017-05-01",
      "completion_date": "2017-07-21",
      "has_results": false,
      "last_update_posted_date": "2017-08-01",
      "last_synced_at": "2026-09-12T09:52:35.640Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03130556"
    },
    {
      "nct_id": "NCT05496231",
      "title": "A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cervical Intraepithelial Neoplasia"
      ],
      "interventions": [
        {
          "name": "HPV9 High formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HPV9 Medium formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HPV9 Low formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gardasil 9",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "26 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 26 Years · Female only"
      },
      "enrollment_count": 1080,
      "start_date": "2022-08-22",
      "completion_date": "2024-02-25",
      "has_results": true,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-09-12T09:52:35.640Z",
      "location_count": 39,
      "location_summary": "San Diego, California • Wheat Ridge, Colorado • Coral Gables, Florida + 33 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05496231"
    },
    {
      "nct_id": "NCT06062069",
      "title": "A Study of CT-868 in Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Overweight",
        "Obese",
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "CT-868",
          "type": "DRUG"
        },
        {
          "name": "CT-868 Pen Injector",
          "type": "DEVICE"
        },
        {
          "name": "CT-868 Pen Injector, Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Carmot Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2023-10-19",
      "completion_date": "2025-07-09",
      "has_results": false,
      "last_update_posted_date": "2025-07-17",
      "last_synced_at": "2026-09-12T09:52:35.640Z",
      "location_count": 22,
      "location_summary": "Concord, California • Escondido, California • Aurora, Colorado + 17 more",
      "locations": [
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06062069"
    },
    {
      "nct_id": "NCT04109222",
      "title": "Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone High-Dose vaccine, 2019-2020 formulation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "83 Years",
        "sex": "ALL",
        "summary": "6 Months to 83 Years"
      },
      "enrollment_count": 90,
      "start_date": "2019-09-30",
      "completion_date": "2019-12-10",
      "has_results": true,
      "last_update_posted_date": "2025-09-12",
      "last_synced_at": "2026-09-12T09:52:35.640Z",
      "location_count": 2,
      "location_summary": "Bardstown, Kentucky • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04109222"
    },
    {
      "nct_id": "NCT02693314",
      "title": "Evaluation of Jarro-Dophilus EPS® Probiotic Formulations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Jarro-Dophilus EPS® (5 billion CFU/capsule)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 75,
      "start_date": "2016-03",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2018-03-23",
      "last_synced_at": "2026-09-12T09:52:35.640Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02693314"
    },
    {
      "nct_id": "NCT02042222",
      "title": "Novel Dose Escalation to Predict Treatment With Hydroxyurea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "1 Year to 16 Years"
      },
      "enrollment_count": 70,
      "start_date": "2013-10",
      "completion_date": "2020-07-31",
      "has_results": false,
      "last_update_posted_date": "2020-11-18",
      "last_synced_at": "2026-09-12T09:52:35.640Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02042222"
    },
    {
      "nct_id": "NCT04762511",
      "title": "A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Herpes Simplex"
      ],
      "interventions": [
        {
          "name": "Lower dose formulation of HSV vaccine (GSK4108771A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Low dose formulation of HSV vaccine (GSK4108771A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Medium dose formulation of HSV vaccine (GSK4108771A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High dose formulation of HSV vaccine (GSK4108771A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 17,
      "start_date": "2021-03-02",
      "completion_date": "2021-05-26",
      "has_results": false,
      "last_update_posted_date": "2021-06-28",
      "last_synced_at": "2026-09-12T09:52:35.640Z",
      "location_count": 2,
      "location_summary": "Lenexa, Kansas • Rochester, New York",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04762511"
    }
  ]
}